Court Bars Abbott From Selling HCV Genotyping Products That Infringe Innogenetics IP | GenomeWeb
NEW YORK (GenomeWeb News) — Innogenetics today said that a US District Court in Wisconsin has barred Abbott Laboratories from using or selling its hepatitis C genotyping technology anywhere in the world after an earlier verdict found Abbott to infringe a US patent held by Innogenetics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.